American Chemical Society
jm6b00469_si_002.csv (1.86 kB)

Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa–Tissue Factor Complex

Download (1.86 kB)
posted on 2016-07-25, 00:00 authored by Xiaojun Zhang, Peter W. Glunz, James A. Johnson, Wen Jiang, Swanee Jacutin-Porte, Vladimir Ladziata, Yan Zou, Monique S. Phillips, Nicholas R. Wurtz, Brandon Parkhurst, Alan R. Rendina, Timothy M. Harper, Daniel L. Cheney, Joseph M. Luettgen, Pancras C. Wong, Dietmar Seiffert, Ruth R. Wexler, E. Scott Priestley
Inhibitors of the tissue factor (TF)/factor VIIa complex (TF-FVIIa) are promising novel anticoagulants which show excellent efficacy and minimal bleeding in preclinical models. Starting with an aminoisoquinoline P1-based macrocyclic inhibitor, optimization of the P′ groups led to a series of highly potent and selective TF-FVIIa inhibitors which displayed poor permeability. Fluorination of the aminoisoquinoline reduced the basicity of the P1 group and significantly improved permeability. The resulting lead compound was highly potent, selective, and achieved good pharmacokinetics in dogs with oral dosing. Moreover, it demonstrated robust antithrombotic activity in a rabbit model of arterial thrombosis.